# REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights

- Source: PR Newswire M&A
- Published: 2026-11-05T12:05:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/regenxbio-reports-third-quarter-2026-financial-results-and-operational-highlights-302930190.html
- Canonical: https://groundlevelnews.com/story/regenxbio-reports-third-quarter-2026-financial-results-and-operational-13203e/

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE® and ASCENT®, expected in Q4 2026 Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._